Phase I evaluation of ICRF-187 (NSC-169780) in patients with advanced malignancy

Cancer. 1981 Apr 15;47(8):1959-62. doi: 10.1002/1097-0142(19810415)47:8<1959::aid-cncr2820470808>3.0.co;2-x.

Abstract

ICRF-187 (NSC-169780), the (+) enantiomer of the racemic antineoplastic agent ICRF-159 (NSc-129943), was administered intravenously for five days every three weeks to 18 patients in a phase I study. Leukopenia was the dose-limiting toxicity. Mild reversible elevations in SGOT and bilirubin were common. Other toxicities were mild and infrequent. Recommended doses of ICRF-187 for phase II studies are 800 mg/m2 for heavily pretreated patients and 1250 mg/m2 for patients with little or no prior therapy. A daily five day intravenous schedule should be used. Other potential clinical uses of ICRF-187 are discussed.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Evaluation
  • Granulocytes
  • Humans
  • Infusions, Parenteral
  • Leukocyte Count / drug effects
  • Leukopenia / chemically induced
  • Myeloproliferative Disorders / chemically induced
  • Neoplasms / drug therapy*
  • Piperazines / therapeutic use*
  • Platelet Count / drug effects
  • Razoxane / administration & dosage
  • Razoxane / adverse effects
  • Razoxane / therapeutic use*

Substances

  • Piperazines
  • Razoxane